Systematic review and network meta-analysis of the efficacy of existing treatments for patients with recurrent glioblastoma (rGBM).

  • Competence Center for Methodology and Statistics
  • Clinical and Epidemiological Investigation Center
  • Public Health Research
April 10, 2021 By:
  • Schritz A
  • Aouali N
  • A. F
  • Dessenne C
  • Berchem G
  • Huiart L
  • Schmitz S.

Background
Despite advances in the treatment of cancers over the last years, treatment options for patients with recurrent glioblastoma (rGBM) remain limited with poor outcomes. Many regimens have been investigated in clinical trials; however, there is a lack of knowledge on comparative effectiveness. The aim of this systematic review is to provide an overview of existing treatment strategies and to estimate the relative efficacy of these regimens in terms of progression free survival (PFS) and overall survival (OS).
Methods
We conducted a systematic review to identify randomized controlled trials (RCTs) investigating any treatment regimen in adult patients suffering from rGBM. Connected studies reporting at least one of our primary outcomes were included in a Bayesian network meta-analysis (NMA) estimating relative treatment effects.
Results
Forty RCTs fulfilled our inclusion criteria evaluating the efficacy of thirty-eight drugs as mono- or combination therapy. Median OS ranged from 2.9 to 18.3 months; median PFS ranged from 0.7 to 6 months. We performed an NMA including 24 treatments that were connected within a large evidence network. Our NMA indicated improvement in PFS with most bevacizumab (BV) based regimens compared to other regimens. We did not find any differences in OS between treatments.
Conclusion
This systematic review provides a comprehensive overview of existing treatment options for rGBM. The NMA provides relative effects for many of these treatment regimens, which have not been directly compared in RCTs. Overall, outcomes for patients with rGBM remain poor across all treatment options, highlighting the need for innovative treatment options.

2021 Apr. Neurooncol Adv. Accepted.
Other information